We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+19.88%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.1B
AUM Growth
+$208M
Cap. Flow
+$144M
Cap. Flow %
13.12%
Top 10 Hldgs %
54.38%
Holding
136
New
36
Increased
27
Reduced
26
Closed
32

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$35.5M
2
NVO
Novo Nordisk
NVO
+$19.7M
3
URGN icon
UroGen Pharma
URGN
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.4M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$10.9M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$19.7M
2
CELG
Celgene Corp
CELG
+$18.8M
3
ITRN icon
Ituran Location and Control
ITRN
+$14.6M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$11.6M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 55.27%
2 Technology 6.57%
3 Consumer Discretionary 1.18%
4 Industrials 1.08%
5 Communication Services 0.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALNA
76
DELISTED
Allena Pharmaceuticals
ALNA
$3.03M 0.28%
431,193
+85,994
+25% +$623K
AAP icon
77
Advance Auto Parts
AAP
$3.35B
$2.97M 0.27%
+17,400
New +$2.81M
WAB icon
78
Wabtec
WAB
$49.1B
$2.95M 0.27%
+40,000
New +$2.88M
ARVN icon
79
Arvinas
ARVN
$518M
$2.92M 0.27%
198,053
-73,000
-27% -$1.29M
DCPH
80
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$2.67M 0.24%
115,033
– –
PRQR icon
81
ProQR Therapeutics
PRQR
$243M
$2.63M 0.24%
190,000
-150,000
-44% -$2.24M
AUDC icon
82
AudioCodes
AUDC
$244M
$2.59M 0.24%
+187,045
New +$2.46M
VTGN icon
83
VistaGen Therapeutics
VTGN
$9.89M
$2.59M 0.24%
67,402
+18,271
+37% +$797K
RDWR icon
84
Radware
RDWR
$1.1B
$2.15M 0.2%
+82,277
New +$2.01M
IMTX icon
85
Immatics
IMTX
$1.18B
$2.07M 0.19%
200,000
– –
CTMX icon
86
CytomX Therapeutics
CTMX
$675M
$1.97M 0.18%
183,151
-90,000
-33% -$1.33M
GILT icon
87
Gilat Satellite Networks
GILT
$834M
$1.48M 0.14%
176,406
+9,743
+6% +$87.6K
KRNT icon
88
Kornit Digital
KRNT
$705M
$1.46M 0.13%
61,404
+31,062
+102% +$661K
FBRX icon
89
Forte Biosciences
FBRX
$1.57B
$1.3M 0.12%
+320
New +$1.24M
ACER
90
DELISTED
Acer Therapeutics Inc
ACER
$1.22M 0.11%
+50,000
New +$1.18M
DK icon
91
Delek US
DK
$4.16B
$1.1M 0.1%
+30,157
New +$1.03M
MRSN
92
DELISTED
Mersana Therapeutics
MRSN
$1.05M 0.1%
+8,000
New +$1.01M
CHRS icon
93
Coherus Oncology
CHRS
$217M
$1.03M 0.09%
+75,600
New +$1.01M
PHXM
94
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$912K 0.08%
12,000
– –
TEVA icon
95
Teva Pharmaceuticals
TEVA
$40.8B
$844K 0.08%
53,834
-650,666
-92% -$11.5M
MGTX icon
96
MeiraGTx Holdings
MGTX
$1.09B
$623K 0.06%
36,159
-35,000
-49% -$493K
CNST
97
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$544K 0.05%
40,162
-30,000
-43% -$269K
FSTX
98
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$535K 0.05%
12,754
– –
CUE icon
99
Cue Biopharma
CUE
$113M
$387K 0.04%
1,667
– –
CRVS icon
100
Corvus Pharmaceuticals
CRVS
$1.12B
$336K 0.03%
83,607
-237,823
-74% -$1M
2 3
4
5 6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2019 Portfolio in Review

As of Q1 2019, Sphera Funds Management held 136 positions worth $1.1B, up 23% from $887M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sphera Funds Management deployed $144M of net new capital in Q1 2019, opening 36 new positions and adding to 27 existing holdings. Its largest new stake was Johnson & Johnson: 265,000 shares worth $37M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 60% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Viatris, an estimated $19.7M trimmed.

  • Sphera Funds Management's largest Q1 2019 buy was Johnson & Johnson: 265,000 shares worth $37M.
  • Sphera Funds Management added most to Bristol-Myers Squibb in Q1 2019, an estimated $12.4M increase.
  • Sphera Funds Management's biggest Q1 2019 reduction was Viatris, cutting an estimated $19.7M.
  • Sphera Funds Management fully exited Ituran Location and Control in Q1 2019, selling an estimated $14.6M.
  • Sphera Funds Management's ten largest holdings make up 54% of its $1.1B portfolio in Q1 2019.
  • Sphera Funds Management opened 36 new positions and closed 32 in Q1 2019.
  • Sphera Funds Management's portfolio value rose 23% quarter-over-quarter to $1.1B.

Based on Sphera Funds Management's 13F filing for Q1 2019, filed 15 May 2019.